New – direct oral anticoagulants: actual review

Czech version

Authors: Jana Michalcová; Miroslav Penka; Alena Buliková; Jiřina Zavřelová; Andrea Štěpařová
Authors‘ workplace: Oddělení klinické hematologie FN Brno, pracoviště Bohunice
Published in: Vnitř Lék 2016; 62(10): 805-813
Category: Reviews

Overview

In recent years the options of anticoagulant/antithrombotic therapy have extended with new – direct oral anticoagulants, comprising direct thrombin inhibitors (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban). These agents represent another progress towards “the ideal antithrombotic drug“, and thus towards a safe and effective antithrombotic therapy. The following article provides actual review and recommendations for clinical practice, including laboratory assessment and management of emergency situations. The approval of idarucizumab as a specific antidote for dabigatran has marked an important step in safety of this treatment.

Key words:
apixaban – dabigatran – DOAC – NOAC – rivaroxaban

Sources

1. The European Medicines Agency. Souhrn údajů o přípravku Pradaxa. [online]. Dostupné z WWW: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.

2. The European Medicines Agency. Souhrn údajů o přípravku Xarelto. [online]. Dostupné z WWW: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.

3. The European Medicines Agency. Souhrn údajů o přípravku Eliquis. [online]. Dostupné z WWW: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf.

4. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361(12): 1139–1151. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0905561>. Erratum in N Engl J Med 2010; 363(19): 1877.

5. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365(10): 883–891. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1009638>.

6. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981–992. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1107039>.

7. Čihák R, Haman L, Táborský M. Aktualizovaná Praktická doporčení European Heart Rhythm Association pro použití nových perorálních antikoagulancií u pacientů s nevalvulární fibrilací síní. Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa 2016; 58(1): 143–164.

8. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. Chest 2016; 149(2): 315–352. Dostupné z DOI: <http://dx.doi.org/10.1016/j.chest.2015.11.026>.

9. Bultas J, Karetová D. Výběr nemocných k léčbě NOAC – co zohlednit? Int Med Prax 2015; 17(3): 118–122.

10. Larsen TB, Rasmussen LH, Skjøth F et al. Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation. J Am Coll Cardiol 2013; 61(22): 2264–2273. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.03.020>.

11. Lauffenburger JC, Farley JF, Gehi AK et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015; 4(4). pii: e001798. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.115.001798>.

12. Kvasnička J, Penka M, Kvasnička T et al. Doporučení České společnosti pro trombózu a hemostázu České lékařské společnosti J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulancii (NOAC) – dabigatran etexilátem, apixabanem a rivaroxabanem. Vnitř Lék 2015; 61(6): 537–546.

13. Baglin T, Keeling D, Kitchen S et al. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2012; 159(4): 427–429. Dostupné z DOI: <http://dx.doi.org/10.1111/bjh.12052>.

14. Cuker A. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis 2016; 41(2): 241–247. Dostupné z DOI: <http://dx.doi.org/10.1007/s11239–015–1282–7>.

15. Francart SJ, Hawes EM, Deal AM et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban: A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 2014; 111(6): 1133–1140. Dostupné z DOI: <http://dx.doi.org/10.1160/TH13–10–0871>.

16. Tripodi A, Padovan L, Testa S et al. How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. Clin Chem Lab Med 2015; 53(2). 265–273. Dostupné z DOI: <http://dx.doi.org/10.1515/cclm-2014–053>.

17. Funk DM. Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program 2012; 2012: 460–465. Dostupné z DOI: <http://dx.doi.org/10.1182/asheducation-2012.1.460>.

18. Hylek EM, Held C, Alexander JH et al. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or WarfarinThe ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014; 63(20): 2141–2147. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2014.02.549>.

19. Washam JB, Piccini JP. Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants? J Thromb Thrombolysis 2016; 41(2): 279–284.

20. Doporučení České společnosti pro trombózu a hemostázu 2015: Postup při krvácení a perioperační management u nemocných léčených novými perorálními antikoagulancii (NOACs): dabigatran-etexilát (PRADAXATM), rivaroxaban (XARELTOTM) a apixaban (ELIQUISTM). Dostupné z WWW: http://www.csth.cz/soubory/csth-postup-pri-krvaceni.pdf.

21. Weitz JI, Pollack CV Jr. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants: Thromb and Haemost 2015; 114(6): 1113–1126. Dostupné z DOI: <http://dx.doi.org/10.1160/TH15–03–0222>.

22. Glund S, Stangier J, Schmohl M et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386(9994): 680–690. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)60732–2>.

23. Penka M, Michalcová J, Zavřelová J et al. Idarucizumab (Praxbind^®) – studie RE-VERSE AD. Hypertenze Kardiovask Prevence 2016; 5(1): 54–60.

24. Václavík J. Antidotum dabigatranu idarucizumab již můžeme využívat v praxi. Cor Vasa 2016; 58: 18–20.

25. Becker RC. The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes. J Thromb Thrombolysis 2016; 41(2): 273–278.

26. Mo Y, Yam FK. Recent Advances in the Development of Specific Antidotes for Target-Specific Oral Anticoagulants. Pharmacotherapy 2015; 35(2): 198–207. Dostupné z DOI: <http://dx.doi.org/10.1002/phar.1532>.

27. Dincq AS, Lessire S, Douxfils J et al. Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. Biomed Res Int 2014; 2014: :385014. Dostupné z DOI: <http://dx.doi.org/10.1155/2014/385014>.